A Change of Paradigm in the Treatment of Cervical Cancer

this guideline on an S3 level was performed. This S3 guideline has led to a change of paradigm in the treatment of cervical cancer. With consideration of all relevant currently published studies a principle of unimodal therapy of cervical cancer should be preferred. This means that all patients with histopathologically documented risk factors, e.g., stages G3, L1, or V1 or bulky disease, which in the past would have been treated by surgery, followed by adjuvant radiochemotherapy, are now advised to receive radiochemotherapy alone and to avoid a surgical approach. This shift of paradigm in the treatment of cervical cancer patients and several other new developments in the surgical and radiooncological treatment of cervical cancer are the scope of this issue of Oncology Research and Treatment: The current recommendations on cervical cancer screening as well as a discussion of cytology versus HPV based screening are given by Hillemanns et al. [1]. Ulrich and Brucker [2] discuss new developments in surgical treatment of early cervical cancer, Dirk Vordermark [3] gives an overview on radiotherapy, while Mallmann and Mallmann [4] give an update on chemotherapy and Tempfer and Beckmann [5] describe the possibilities of novel agents in the treatment of recurrent cervical cancer.